2012
DOI: 10.1016/j.euroneuro.2012.03.009
|View full text |Cite
|
Sign up to set email alerts
|

Pre-treatment waking cortisol response and vulnerability to interferon α induced depression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
4
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 24 publications
1
4
0
Order By: Relevance
“…Promising findings from studies awaiting replication include genetic polymorphisms coding for phospholipase A2, cyclooxygenase 2 [15] and the serotonin transporter protein 5-HTTLPR [16]. Additionally we recently reported an enhanced baseline reactivity of the hypothalamicpituitary-adrenal axis, as measured by waking salivary cortisol secretion, to be associated with later MDD emergence during IFNα treatment [17]. This is consistent with preliminary findings in non-iatrogenic depression.…”
Section: Introductionsupporting
confidence: 63%
“…Promising findings from studies awaiting replication include genetic polymorphisms coding for phospholipase A2, cyclooxygenase 2 [15] and the serotonin transporter protein 5-HTTLPR [16]. Additionally we recently reported an enhanced baseline reactivity of the hypothalamicpituitary-adrenal axis, as measured by waking salivary cortisol secretion, to be associated with later MDD emergence during IFNα treatment [17]. This is consistent with preliminary findings in non-iatrogenic depression.…”
Section: Introductionsupporting
confidence: 63%
“…Recently Huckans et al also reported increased symptoms of depression during interferon therapy in a cohort of 33 HCV infected patients, which decreased or remitted following treatment discontinuation [ 42 ]. Eccles et al have demonstrated that hypothalamic-pituitary-adrenal axis hyperactivity prior to interferon based therapy evaluated through measurement of the waking salivary cortisol response was associated to depression during treatment [ 43 ]. Whale et al showed recently that younger age, previous history of major depression disorder, higher baseline psychomotor retardation and somatic symptoms item scores using the Hamilton Depression Rating Scale and HCV genotype 2 were implicated in depression during IFN treatment [ 44 ].…”
Section: Discussionmentioning
confidence: 99%
“…Often it is not so much the possible somatic side effects such as thyroid dysfunction, headache and anemia but frequent psychic side effects that impair the health-related quality of life of those affected. Many patients develop a IFN-α-induced depressive symptomatology that usually appears within three months after the start of IFN-α treatment [ 5 , 9 13 ].…”
Section: Introductionmentioning
confidence: 99%